103 Blood biomarkers during and after treatment Table 1 Continued. Missing Valvular disease 2 (2%) Heart failure 8 (9%) Any new pulmonary event 19 (22%) Pneumonia 8 (9%) Respiratory failure 9 (10%) Progressive or new COPD 3 (3%) Available lab values at follow up Baseline 87 (100%) End of treatment 81 (93%) 4 weeks 79 (91%) 6 months 65 (75%) 1 year 49 (56%) 2 years 33 (38%) Reasons for stopping early Death, tumor related 26 (30%) Death, non-tumor related 14 (16%) Stopped because of progressive disease 12 (14%) Stopped, other reason 2 (2%) * All patients scored with MI were scored having CI as well Abbreviations: AC: adenocarcinoma, SCC: squamous cell carcinoma, SE: standard error Mean age was 67.1 years old and 33 out of 87 patients (38%) had a history of cardiac events prior to treatment. The majority, 51 out of 87 patients (59%), underwent surgery after nCRT and only 5 patients were treated with dRT. Patients who underwent surgery were significantly younger (mean 65 vs. 70 years old, p<0.01), were less likely to have a cardiac event history (29 vs. 50%, p=0.05), but experienced significantly more cardiac complications during follow up (37% vs 17%, p=0.04). At one year, only 49/87 patients were available for analyses. The majority (38/87) of patients stepped out earlier because of tumor progression or tumor related death. Details on follow up data regarding survival, tumor recurrence and on cardiac and pulmonary events are presented in Table 1. All events occurred during follow up(within 2 years after treatment), but not during treatment. Twenty five patients (29%) developed a new cardiac event, while 19 patients (22%) experienced a new pulmonary event. Significant associations were found between several lung dose parameters and pulmonary events. The lung V5 7
RkJQdWJsaXNoZXIy MTk4NDMw